Cargando…

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance therapy. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stark, Dan P., Cook, Adrian, Brown, Julia M., Brundage, Michael D., Embleton, Andrew C., Kaplan, Richard S., Raja, Fharat A., Swart, Ann Marie W., Velikova, Galina, Qian, Wendi, Ledermann, Jonathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516140/ https://www.ncbi.nlm.nih.gov/pubmed/28339098 http://dx.doi.org/10.1002/cncr.30657

Ejemplares similares

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
por: Raja, F A, et al.
Publicado: (2011)

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
por: Ledermann, J.A., et al.
Publicado: (2021)

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
por: Stark, Dan, et al.
Publicado: (2013)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
por: Oza, Amit M, et al.
Publicado: (2015)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application
por: Embleton-Thirsk, Andrew, et al.
Publicado: (2019)

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
por: González Martín, Antonio, et al.
Publicado: (2019)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

Impact of retrospective data verification on the results of the academic-led ICON6 trial
por: Embleton, Andrew, et al.
Publicado: (2015)

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy
por: Milani, Andrea, et al.
Publicado: (2017)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
por: Clamp, Andrew R, et al.
Publicado: (2019)

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)
por: Colomban, Olivier, et al.
Publicado: (2020)

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
por: Blagden, Sarah P, et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
por: Clamp, Andrew R, et al.
Publicado: (2022)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma
por: Lobo, Merryl R., et al.
Publicado: (2015)

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
por: Lee, Jung-Min, et al.
Publicado: (2022)

Icones Roumaines
por: Nicolescu, Corina
Publicado: (1971)

Phonological iconicity
por: Schmidtke, David S., et al.
Publicado: (2014)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
por: Lobo, Merryl R., et al.
Publicado: (2014)

Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray
por: Jiang, Wenhua, et al.
Publicado: (2017)

Limits to the usability of iconic memory
por: Rensink, Ronald A.
Publicado: (2014)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

The equations: icons of knowledge
por: Bais, Sander
Publicado: (2005)

The Birth of an Anatomical Icon
Publicado: (1999)

ICON: chronic rhinosinusitis
por: Bachert, Claus, et al.
Publicado: (2014)

ICON: Eosinophil Disorders
por: Valent, Peter, et al.
Publicado: (2012)

Iconic gesturing in bonobos
por: Genty, Emilie, et al.
Publicado: (2015)

ICON 2020 Supplement
por: Saeed, Saima, et al.
Publicado: (2020)

ICON 2022 Supplement
por: Amanullah, Farhana, et al.
Publicado: (2022)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
por: Lheureux, Stephanie, et al.
Publicado: (2023)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Effects of Users’ Familiarity With the Objects Depicted in Icons on the Cognitive Performance of Icon Identification
por: Shen, Zhangfan, et al.
Publicado: (2018)

Icons of architecture : the 20th century /
Publicado: (1998)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
por: Suffredini, Dante A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3fqm1dkold8cbtudufm3p910qe